Regeneron Pharmaceuticals (REGN) Capital Leases (2009 - 2025)

Regeneron Pharmaceuticals' Capital Leases history runs 16 years deep, the most recent figure standing at $720.0 million for Q4 2025.

• On a quarterly basis, Capital Leases changed 0.0% year-over-year to $720.0 million in Q4 2025; TTM through Dec 2025 was $720.0 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $720.0 million, changed 0.0% from the prior year.
• Capital Leases held at $720.0 million in Q4 2025 per REGN's latest filing, from $720.0 million in the prior quarter.
• Across five years, Capital Leases topped out at $720.0 million in Q1 2022 and bottomed at $720.0 million in Q1 2022.
• The 4-year median for Capital Leases is $720.0 million (2022), against an average of $720.0 million.
• Biggest YoY gain for Capital Leases was 0.0% in 2023; the steepest drop was 0.0% in 2023.
• Year by year, Capital Leases stood at $720.0 million in 2022, then changed by 0.0% to $720.0 million in 2023, then changed by 0.0% to $720.0 million in 2024, then changed by 0.0% to $720.0 million in 2025.
• Per Business Quant, the three latest REGN Capital Leases figures stand at $720.0 million (Q4 2025), $720.0 million (Q3 2025), and $720.0 million (Q2 2025).